Cyrus offers an easy-to-use cloud pipeline using SparksX software package to accelerate drug development
Seattle, and Indianapolis, October 8, 2015 – Cyrus Biotechnology has signed a software licensing agreement with Indiana University Research and Technology Corporation (IURTC) at Indiana University (IU) to commercialize the SparksX software package developed at the lab of former IU professor Yaoqi Zhou at the Indianapolis campus.
Cyrus offers a highly automated protein structure prediction and design software-as-a-service (SaaS) package, “Cyrus Bench”, for both bench scientists and computational biologists/chemists.
SparksX, combined with Rosetta from David Baker’s lab at the University of Washington (UW) and licensed to Cyrus, leads the competition in protein homology modeling, both in the biennial CASP and weekly CAMEO “blinded” competitions.
SparksX, developed by Zhou and his team, recognizes protein folds and identifies “deep” (difficult to detect) protein sequence similarity, or homology, better than any other software package, winning first place in CASP 6.
The Cyrus founding team brings decades of protein modeling and high-performance computing experience, with UW Professor David Baker, scientific advisor, Lucas Nivon, CEO, Yifan Song, CSO, Javier Castellanos, CTO.
“As a powerful tool for molecular modeling, SparksX is positioned to help further establish Cyrus as a leader in the drug development space. They have a suite of products that were originally developed through academic work across multiple universities, and Cyrus is a fine example of how startup ventures can further the impact of such research and translate these developments into the marketplace. We are delighted to partner with the Cyrus team to bring the SparksX software to market”, said Marie Kerbeshian, VP of Technology Commercialization at IURTC.
Cyrus is thrilled to announce the addition of Rosario Caltabiano to our Executive Team as Executive VP of Sales.
Rosario is a fervent customer advocate and successful professional with a high level of integrity. He brings over fifteen years of experience in sales and management with a consistent and successful growth track record, having worked in small and large companies, including Accelrys, IBM, and Interactive Supercomputing. His strong focus on bringing computationally intensive, scientific software to R&D organizations is a winning formula for Cyrus Biotechnology and its valued customers.
At Accelrys, a leading provider of enterprise scientific software to the Biotech, Chemical and Pharmaceutical industries, Rosario more than doubled his business in just three years, and was the top performer company-wide in 2012. At Interactive Supercomputing, a start-up offering parallel computing software, Rosario’s team acquired 50 new US customers in just two years. At IBM, Alliant Computer Systems and SGI, Rosario had strong exposure to in-silico molecular simulation software and collaborated with scientists and researchers in various technical and sales roles.
He earned a Master’s Degree, Summa Cum Laude, in Electrical Engineering from Universita` degli Studi di Napoli, Italy.
Cyrus Biotech’s CEO, Lucas Nivon, was interviewed at the WBBA’s LSINW, talking about software opportunities in the cloud for the Biotech and Pharma industries.
Cyrus Biotech CEO Lucas Nivon presented a summary of the Cyrus software package’s features and target use cases at the Life Sciences Innovation Northwest (LSINW) on July 1, 2015. Cyrus CEO Lucas Nivon at LSINW
Puget Sound Business Journal has published a concise summary of Cyrus’ software and our mission — to accelerate drug development with powerful new software deployed on the cloud. Puget Sound Business Journal Article.
Geekwire profiles our licensing of Rosetta software and our plans to develop an easy-to-use version of Rosetta aimed at working scientists. Geekwire Article
Announcing Cyrus Biotechnology’s licensing of Rosetta software from the University of Washington, and our initial funding! We are thrilled to be launched with terrific support from everyone at the UW, especially David Baker and his IPD and UW’s CoMotion technology transfer office.